A Phase 3, Open-label, Randomized Parallel,2-arm,Multi-center Study Of Talazoparib(Bmn 673) Versus Physician's Choice In Germline Brca Mutation Subjects With Locally Advanced And/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens For Metastatic Disease

Trial Profile

A Phase 3, Open-label, Randomized Parallel,2-arm,Multi-center Study Of Talazoparib(Bmn 673) Versus Physician's Choice In Germline Brca Mutation Subjects With Locally Advanced And/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens For Metastatic Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Talazoparib (Primary) ; Capecitabine; Eribulin; Gemcitabine; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBRACA
  • Sponsors BioMarin Pharmaceutical; Medivation; Pfizer
  • Most Recent Events

    • 12 Dec 2017 According to a Myriad Genetics media release, data from this trial were presented last week at the 2017 San Antonio Breast Cancer Symposium (SABCS).
    • 09 Dec 2017 Results (n=431) assessing efficacy presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 08 Dec 2017 According to a Pfizer media release, data from the study will be presented as an oral presentation at the 2017 San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top